Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Baseline sodium, bicarbonate, BUN, vitamin D, HDL, CRP, PTH and albumin were lower in RD compared to non-RD (S1 Table in S1 File).

Source: RD vs non-RD. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cohort study.

Cohort study

Examines exposures and outcomes over time within a defined group.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

A retrospective cohort study was performed among patients with incident ADPKD (1/1/2002-12/31/2018).

Source: Abstract.

Patients were required to have ≥ 2 diagnosis codes on 2 separate encounter dates (which may have been consecutive days) from inpatient, emergency department (ED), or ambulatory care settings.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Data driven approach to characterize rapid decline in autosomal dominant polycystic kidney disease

Cohort study · PLOS ONE · 2024

Original publication title

Data driven approach to characterize rapid decline in autosomal dominant polycystic kidney disease

John J. Sim; Yu-Hsiang Shu; Simran K. Bhandari; Qiaoling Chen; Teresa N. Harrison; Min Young Lee; Mercedes A. Munis; Kerresa Morrissette; Shirin Sundar; Kristin Pareja; Ali Nourbakhsh; Cynthia J. Willey

© 2024 Sim et al

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Autosomal dominant polycystic kidney disease (ADPKD) is a genetic kidney disease with high phenotypic variability. Furthering insights into patients’ ADPKD progression could lead to earlier detection, management, and alter the course to end stage kidney disease (ESKD). We sought to identify patients with rapid decline (RD) in kidney function and to determine clinical factors associated with RD using a data-driven approach. A retrospective cohort study was performed among patients with incident ADPKD (1/1/2002-12/31/2018). Latent class mixed models were used to identify RD patients using differences in eGFR trajectories over time.

Predictors of RD were selected based on agreements among feature selection methods, including logistic, regularized, and random forest modeling. The final model was built on the selected predictors and clinically relevant covariates. Among 1,744 patients with incident ADPKD, 125 (7%) were identified as RD. Feature selection included 42 clinical measurements for adaptation with multiple imputations; mean (SD) eGFR was 85.2 (47.3) and 72.9 (34.4) in the RD and non-RD groups, respectively. Multiple imputed datasets identified variables as important features to distinguish RD and non-RD groups with the final prediction model determined as a balance between area under the curve (AUC) and clinical relevance which included 6 predictors: age, sex, hypertension, cerebrovascular disease, hemoglobin, and proteinuria.

Results showed 72%-sensitivity, 70%-specificity, 70%-accuracy, and 0.77-AUC in identifying RD. 5-year ESKD rates were 38% and 7% among RD and non-RD groups, respectively. Using real-world routine clinical data among patients with incident ADPKD, we observed that six variables highly predicted RD in kidney function.

Authors’ abstract

Autosomal dominant polycystic kidney disease (ADPKD) is a genetic kidney disease with high phenotypic variability. Furthering insights into patients’ ADPKD progression could lead to earlier detection, management, and alter the course to end stage kidney disease (ESKD). We sought to identify patients with rapid decline (RD) in kidney function and to determine clinical factors associated with RD using a data-driven approach. A retrospective cohort study was performed among patients with incident ADPKD (1/1/2002-12/31/2018). Latent class mixed models were used to identify RD patients using differences in eGFR trajectories over time.

Predictors of RD were selected based on agreements among feature selection methods, including logistic, regularized, and random forest modeling. The final model was built on the selected predictors and clinically relevant covariates. Among 1,744 patients with incident ADPKD, 125 (7%) were identified as RD. Feature selection included 42 clinical measurements for adaptation with multiple imputations; mean (SD) eGFR was 85.2 (47.3) and 72.9 (34.4) in the RD and non-RD groups, respectively. Multiple imputed datasets identified variables as important features to distinguish RD and non-RD groups with the final prediction model determined as a balance between area under the curve (AUC) and clinical relevance which included 6 predictors: age, sex, hypertension, cerebrovascular disease, hemoglobin, and proteinuria.

Results showed 72%-sensitivity, 70%-specificity, 70%-accuracy, and 0.77-AUC in identifying RD. 5-year ESKD rates were 38% and 7% among RD and non-RD groups, respectively. Using real-world routine clinical data among patients with incident ADPKD, we observed that six variables highly predicted RD in kidney function.

Publication and source details

Original title: Data driven approach to characterize rapid decline in autosomal dominant polycystic kidney disease

John J. Sim; Yu-Hsiang Shu; Simran K. Bhandari; Qiaoling Chen; Teresa N. Harrison; Min Young Lee; Mercedes A. Munis; Kerresa Morrissette; Shirin Sundar; Kristin Pareja; Ali Nourbakhsh; Cynthia J. Willey

PLOS ONE · 2024

Competing Interests: Shirin Sundar, Kristin Pareja, and Ali Nourbakhsh are current or former employees of Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ. Cynthia J. Willey has worked as a paid consultant for Otsuka Pharmaceuticals Development & Commercialization. John J. Sim currently has or has had research grant support from Otsuka Pharmaceutical Development & Commercialization, Vera Pharmaceuticals, Astra Zeneca Pharmaceuticals, NIH/Kidney Nutrition Obesity and Diabetes Study Section (co-investigator w Manjula Tamura PI), and Kaiser Permanente Southern California clinician investigator award.

This does not alter our adherence to PLOS ONE policies on sharing data and materials.

* E-mail: John.J.Sim@kp.org
© 2024 Sim et al2024Sim et alhttps://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. http://dx.doi.org/10.13039/100015303Otsuka Pharmaceutical Development and Commercialization https://orcid.org/0000-0001-9456-8243 Sim John J. This study was funded by a research grant from Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ. (PI: JJS). The funder provided support in the form of salaries for authors SS, KP, and AN. The funder was involved in the study design and preparation of the manuscript. The funder did not have any additional roles in the data collection and analysis, or decision to publish.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T11:07:43.120117+00:00

DOI: 10.1371/journal.pone.0298484 · PMC11152279